2Anderson FA Jr, Wheeler HB, Goldberg RJ, et al.A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT Study.Arch Intern Med,1991,151:933-938.
4Urokinase Pulmonary embolism trial: a national cooperative study. Circulation ,1973, 47:1-108.
5Goldhaber SZ, Kessler CM, Heit J, et al.Randomised controlled trial of recombinant tissue plasminogen activator versus urokinase in the treatment of acute pulmonary embolism.Lancet,1988,2:293-298.
6Goldhaber SZ. Evolving concepts in thrombolytic therapy for pulmonary embolism.Chest,1992,101(4 Suppl):183S-185S.
7Daniels LB, Parker JA, Patel SR, et al.Relation of duration of symptoms with response to thrombolytic therapy in pulmonary embolism.Am J Cardiol, 1997,80:184-188.
8Arcasoy SM, Kreit JW.Thrombolytic therapy of pulmonary embolism: a comprehensive review of current evidence.Chest,1999,115:1695-1707.
9Bergqvist D,Lindblad B.A 30-year survey of pulmonary embolism verified at autopsy:an analysis of 1274 surgical patients.Br J Surg ,1985,72:105-108.
10Samkoff JS, Comstock GW. Epidemiology of pulmonary embolism:mortality in a general population. Am J Epidemiol, 1981,114:488-496.
